BANGUNAWATI RAHAJENG (1); Prof. Dr. apt. Zullies Ikawati. (2); Prof. Dr. Tri Murti Andayani, Sp.FRS., Apt. (3); Prof. dr. Iwan Dwiprahasto, M.Med.Sc., Ph.D. (4)
Tanggal/Date
2018
Kata Kunci/Keyword
Abstrak/Abstract
Objective:. In Indonesia, carbamazepine was approved by The National Agency of Drugs And Foods Controls for the prophylaxis of lithium unresponsive manic-depressive disorders, all types of epilepsy (except for petit mal), and trigeminal neuralgia. This study was conducted to determine the off-label use of carbamazepine in Indonesia.
Methods: This research is a nonexperimental descriptive study with a cross-sectional method. Data collection retrospectively by taking all patients that were prescribed carbamazepine in 2014. Data were obtained from four general hospitals in Yogyakarta. The off-label use of carbamazepine was defined a prescribing of carbamazepine outside the indication that approved by The National Agency for Drugs And Foods Controls of Republic of Indonesia (NA-DFC).
Results: The use of carbamazepine in 2014 were 704 prescriptions, and on 251 (35.6%) of them were off-label drug use. The off-label use of carbamazepine were 149 prescriptions (59.4%) for neuropathic pain, 83 prescriptions (33.0%) for nociceptive pain, and 19 prescriptions (7.6%) for other indications.
Conclusion: The mostly off-label use of carbamazepine in Indonesia was in neuropathic pain with low evidence. Further research to study the efficacy and the risk of off-label use of carbamazepine may be an essential step toward defining the potential for such purpose.
Rumpun Ilmu
Farmakologi dan Farmasi Klinik
Bahasa Asli/Original Language
English
Level
Internasional
Status
Dokumen Karya
No
Judul
Tipe Dokumen
Aksi
1
11_ AJPCR 2018_Rahajeng et al.pdf
Bukti Published
2
The Off-Label Use of Carbamazepine in Indonesia (2).pdf
